| 48.0177 -4.082 (-7.84%) | 06-05 13:58 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 58.79 |
1-year : | 61.69 |
| Resists | First : | 50.33 |
Second : | 52.81 |
| Pivot price | 49.92 |
|||
| Supports | First : | 46.31 |
Second : | 38.53 |
| MAs | MA(5) : | 51.13 |
MA(20) : | 49.78  |
| MA(100) : | 44.31 |
MA(250) : | 41.2 |
|
| MACD | MACD : | 1.1 |
Signal : | 1.3 |
| %K %D | K(14,3) : | 63.2 |
D(3) : | 83.1 |
| RSI | RSI(14): 46.2 |
|||
| 52-week | High : | 52.81 | Low : | 33.38 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ CBSE ] has closed above bottom band by 18.3%. Bollinger Bands are 42.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 49.64 - 49.94 | 49.94 - 50.16 |
| Low: | 47.35 - 47.74 | 47.74 - 48.03 |
| Close: | 47.54 - 48.12 | 48.12 - 48.55 |
The ETF seeks to replicate the performance of the Bloomberg World All-Cap Equal Weight TR Index.
Wed, 20 May 2026
ImmunityBio stock climbs as FDA accepts expanded use filing for bladder cancer drug - MSN
Wed, 20 May 2026
ImmunityBio Stock Climbs As FDA Accepts Expanded Use Filing For Bladder Cancer Drug - Benzinga
Mon, 04 May 2026
CLNN Stock Rises 8% – Here’s What The FDA Update Means For Clene’s ALS Treatment - Stocktwits
Tue, 21 Apr 2026
Clough Capital’s Actively Managed ETF Platform Surpasses $100 Million in Assets Under Management - Business Wire
Fri, 14 Nov 2025
Clough Capital Marks Five Year Anniversary of Actively Managed ETFs - Yahoo Finance
Mon, 03 Mar 2025
Clough Capital Celebrates 25 Years of Investment Management Perspective & Discipline - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
AMEX
|
|
|
Sector:
Financial Services
|
|
|
Industry:
Asset Management - Bonds
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|